Occurrence of solicited symptoms during the 7-day follow-up period, unsolicited symptoms during the 30-day follow-up period, grade 3 vaccine related local and general symptoms during the 30-day follow-up and serious adverse events during the entire study
Immunogenicity as assessed by humoral and CMI response.
18 Years to 50 Years (Adult)
September 7, 2005
May 30, 2017
GSK Investigational Site Lausanne, Switzerland
† Study has passed its completion date and status has not been verified in more than two years.